{"transactions":[{"id":823599,"issuer":{"id":7215,"kind":"organization","name":"Genenta Science S.p.A."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO& Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-01T20:05:27.000Z","date":"2026-03-30","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in equal monthly installments over one year beginning March 30, 2026."}],"balance_after":20000,"derivative":{"exercise_price":0.63,"expiration_date":"2035-12-31","underlying":"American Depositary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-26-014634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1838716/000149315226014634/ownership.xml","form_type":"4"}},{"id":1486857,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:10:59.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":375077,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares shall vest in forty-eight (48) equal monthly installaments following January 26, 2024, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates."}],"balance_after":375077,"derivative":{"exercise_price":2.53,"expiration_date":"2034-01-25","underlying":"Common Stock","underlying_shares":375077},"source":{"system":"sec-edgar","filing":"0000950170-24-070630","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024070630/ownership.xml","form_type":"4"}},{"id":1669588,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-27T00:11:41.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":288134,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates."}],"balance_after":288134,"derivative":{"exercise_price":2.4,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":288134},"source":{"system":"sec-edgar","filing":"0000950170-24-008051","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024008051/ownership.xml","form_type":"4"}},{"id":1669587,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-27T00:11:41.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":26300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person was issued RSUs. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2025. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":101801,"source":{"system":"sec-edgar","filing":"0000950170-24-008051","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024008051/ownership.xml","form_type":"4"}},{"id":1669586,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-27T00:11:41.000Z","date":"2024-01-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":4957,"price":2.4,"value":11896.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":75501,"source":{"system":"sec-edgar","filing":"0000950170-24-008051","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024008051/ownership.xml","form_type":"4"}},{"id":1767615,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-10-03T20:24:27.000Z","date":"2023-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":8093,"price":1.37,"value":11087.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":80458,"source":{"system":"sec-edgar","filing":"0001209191-23-051473","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123051473/doc4.xml","form_type":"4"}},{"id":1805912,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:11:28.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":117200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 24, 2023, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":117200,"derivative":{"exercise_price":2.14,"expiration_date":"2033-01-23","underlying":"Common Stock","underlying_shares":117200},"source":{"system":"sec-edgar","filing":"0001209191-23-046102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046102/doc4.xml","form_type":"4"}},{"id":1805911,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:11:28.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":117200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 24, 2023, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.05,"expiration_date":"2033-01-23","underlying":"Common Stock","underlying_shares":117200},"source":{"system":"sec-edgar","filing":"0001209191-23-046102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046102/doc4.xml","form_type":"4"}},{"id":1805910,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:11:28.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 7, 2022, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":125000,"derivative":{"exercise_price":2.14,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-23-046102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046102/doc4.xml","form_type":"4"}},{"id":1805909,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:11:28.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 7, 2022, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":15.52,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-23-046102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046102/doc4.xml","form_type":"4"}},{"id":1805908,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:11:28.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":26625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"A total of 28,400 shares subject to an employee stock option were granted on February 12, 2023, with the shares subject to this option vesting in forty-eight (48) equal installments on each monthly anniversary following February 12, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. The Reporting Person previously exercised 1,775 shares subject to this option."}],"balance_after":26625,"derivative":{"exercise_price":2.14,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":26625},"source":{"system":"sec-edgar","filing":"0001209191-23-046102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046102/doc4.xml","form_type":"4"}},{"id":1805907,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:11:28.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"A total of 28,400 shares subject to an employee stock option were granted on February 12, 2023, with the shares subject to this option vesting in forty-eight (48) equal installments on each monthly anniversary following February 12, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. The Reporting Person previously exercised 1,775 shares subject to this option."}],"balance_after":0,"derivative":{"exercise_price":16.82,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":26625},"source":{"system":"sec-edgar","filing":"0001209191-23-046102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046102/doc4.xml","form_type":"4"}},{"id":1805906,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:11:28.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":73964,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"A total of 80,000 shares subject to an employee stock option were granted on January 13, 2021, with the shares subject to this option vesting in forty-eight (48) equal installments on each monthly anniversary following January 13, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. The Reporting Person previously exercised 6,036 shares subject to this option."}],"balance_after":73964,"derivative":{"exercise_price":2.14,"expiration_date":"2031-01-12","underlying":"Common Stock","underlying_shares":73964},"source":{"system":"sec-edgar","filing":"0001209191-23-046102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046102/doc4.xml","form_type":"4"}},{"id":1805905,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:11:28.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":73964,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"A total of 80,000 shares subject to an employee stock option were granted on January 13, 2021, with the shares subject to this option vesting in forty-eight (48) equal installments on each monthly anniversary following January 13, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. The Reporting Person previously exercised 6,036 shares subject to this option."}],"balance_after":0,"derivative":{"exercise_price":13.27,"expiration_date":"2031-01-12","underlying":"Common Stock","underlying_shares":73964},"source":{"system":"sec-edgar","filing":"0001209191-23-046102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046102/doc4.xml","form_type":"4"}},{"id":1805904,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:11:28.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":77269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following September 17, 2020, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":77269,"derivative":{"exercise_price":2.14,"expiration_date":"2030-09-16","underlying":"Common Stock","underlying_shares":77269},"source":{"system":"sec-edgar","filing":"0001209191-23-046102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046102/doc4.xml","form_type":"4"}},{"id":1805903,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:11:28.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":77269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following September 17, 2020, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":16.11,"expiration_date":"2030-09-16","underlying":"Common Stock","underlying_shares":77269},"source":{"system":"sec-edgar","filing":"0001209191-23-046102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046102/doc4.xml","form_type":"4"}},{"id":1805902,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:11:28.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":113652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"A total of 128,424 shares subject to an employee stock option were granted to the Reporting Person on September 15, 2020, with 25% of the shares subject to this option vested and exercisable on September 23, 2020, and the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. The Reporting Person previously exercised 14,772 shares subject to this option."}],"balance_after":113652,"derivative":{"exercise_price":2.14,"expiration_date":"2029-10-15","underlying":"Common Stock","underlying_shares":113652},"source":{"system":"sec-edgar","filing":"0001209191-23-046102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046102/doc4.xml","form_type":"4"}},{"id":1805901,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:11:28.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":113652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"A total of 128,424 shares subject to an employee stock option were granted to the Reporting Person on September 15, 2020, with 25% of the shares subject to this option vested and exercisable on September 23, 2020, and the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. The Reporting Person previously exercised 14,772 shares subject to this option."}],"balance_after":0,"derivative":{"exercise_price":5.97,"expiration_date":"2029-10-15","underlying":"Common Stock","underlying_shares":113652},"source":{"system":"sec-edgar","filing":"0001209191-23-046102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046102/doc4.xml","form_type":"4"}},{"id":2045057,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-26T21:08:32.000Z","date":"2023-01-24","kind":"grant","acquired":true,"shares":117200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates."}],"balance_after":117200,"derivative":{"exercise_price":9.05,"expiration_date":"2033-01-23","underlying":"Common Stock","underlying_shares":117200},"source":{"system":"sec-edgar","filing":"0001209191-23-005044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123005044/doc4.xml","form_type":"4"}},{"id":2045056,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-26T21:08:32.000Z","date":"2023-01-24","kind":"grant","acquired":true,"shares":26100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was issued Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2024. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":88551,"source":{"system":"sec-edgar","filing":"0001209191-23-005044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123005044/doc4.xml","form_type":"4"}},{"id":2144776,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-10-04T21:18:35.000Z","date":"2022-10-04","kind":"tax_withholding","acquired":false,"shares":7933,"price":14.22,"value":112807.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":62451,"source":{"system":"sec-edgar","filing":"0001209191-22-052378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122052378/doc4.xml","form_type":"4"}},{"id":2191979,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-08-09T00:31:03.000Z","date":"2022-08-04","kind":"tax_withholding","acquired":false,"shares":5533,"price":18.25,"value":100977.25,"ownership":{"direct":true},"balance_after":70384,"source":{"system":"sec-edgar","filing":"0001209191-22-044904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122044904/doc4.xml","form_type":"4"}},{"id":2191978,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-08-09T00:31:03.000Z","date":"2022-08-04","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person was issued 80,000 Restricted Stock Units (\"RSUs\") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Person's Restricted Stock Unit Agreement. On August 4, 2022, upon the occurrence of the third performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":75917,"source":{"system":"sec-edgar","filing":"0001209191-22-044904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122044904/doc4.xml","form_type":"4"}},{"id":2304626,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-04-05T22:23:50.000Z","date":"2022-04-04","kind":"exercise","acquired":false,"shares":1775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"A total of 28,400 shares subject to an employee stock option were granted on February 12, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates."}],"balance_after":26625,"derivative":{"exercise_price":16.82,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":1775},"source":{"system":"sec-edgar","filing":"0001209191-22-023285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122023285/doc4.xml","form_type":"4"}},{"id":2304625,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-04-05T22:23:50.000Z","date":"2022-04-04","kind":"exercise","acquired":false,"shares":168,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation (\"Old Adicet\"), for $0.740 per share in connection with the merger (the \"Merger\") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation (\"resTORbio\"). On the effective date of the Merger, resTORbio changed its name to \"Adicet Bio, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"A total of 128,424 shares subject to an employee stock option were received as described in footnote (3). 25% of the shares vested on September 23, 2020, and 1/36th of the remaining unvested shares vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting date."}],"balance_after":113652,"derivative":{"exercise_price":5.97,"expiration_date":"2029-10-15","underlying":"Common Stock","underlying_shares":168},"source":{"system":"sec-edgar","filing":"0001209191-22-023285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122023285/doc4.xml","form_type":"4"}},{"id":2304624,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-04-05T22:23:50.000Z","date":"2022-04-04","kind":"exercise","acquired":false,"shares":6036,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"A total of 80,000 shares subject to an employee stock option were granted on January 13, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates."}],"balance_after":73964,"derivative":{"exercise_price":13.27,"expiration_date":"2031-01-12","underlying":"Common Stock","underlying_shares":6036},"source":{"system":"sec-edgar","filing":"0001209191-22-023285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122023285/doc4.xml","form_type":"4"}},{"id":2304623,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-04-05T22:23:50.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":7621,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation (\"Old Adicet\"), for $0.740 per share in connection with the merger (the \"Merger\") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation (\"resTORbio\"). On the effective date of the Merger, resTORbio changed its name to \"Adicet Bio, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"A total of 128,424 shares subject to an employee stock option were received as described in footnote (3). 25% of the shares vested on September 23, 2020, and 1/36th of the remaining unvested shares vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting date."}],"balance_after":113820,"derivative":{"exercise_price":5.97,"expiration_date":"2029-10-15","underlying":"Common Stock","underlying_shares":7621},"source":{"system":"sec-edgar","filing":"0001209191-22-023285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122023285/doc4.xml","form_type":"4"}},{"id":2304622,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:23:50.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":1775,"price":21,"value":37275.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021."}],"balance_after":59917,"source":{"system":"sec-edgar","filing":"0001209191-22-023285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122023285/doc4.xml","form_type":"4"}},{"id":2304621,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:23:50.000Z","date":"2022-04-04","kind":"exercise","acquired":true,"shares":1775,"price":16.82,"value":29855.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021."}],"balance_after":61692,"source":{"system":"sec-edgar","filing":"0001209191-22-023285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122023285/doc4.xml","form_type":"4"}},{"id":2304620,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:23:50.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":168,"price":21,"value":3528.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021."}],"balance_after":59917,"source":{"system":"sec-edgar","filing":"0001209191-22-023285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122023285/doc4.xml","form_type":"4"}},{"id":2304619,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:23:50.000Z","date":"2022-04-04","kind":"exercise","acquired":true,"shares":168,"price":5.97,"value":1002.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021."}],"balance_after":60085,"source":{"system":"sec-edgar","filing":"0001209191-22-023285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122023285/doc4.xml","form_type":"4"}},{"id":2304618,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:23:50.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":6036,"price":21,"value":126756.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021."}],"balance_after":59917,"source":{"system":"sec-edgar","filing":"0001209191-22-023285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122023285/doc4.xml","form_type":"4"}},{"id":2304617,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:23:50.000Z","date":"2022-04-04","kind":"exercise","acquired":true,"shares":6036,"price":13.27,"value":80097.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021."}],"balance_after":65953,"source":{"system":"sec-edgar","filing":"0001209191-22-023285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122023285/doc4.xml","form_type":"4"}},{"id":2304616,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:23:50.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":7621,"price":21,"value":160041.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021."}],"balance_after":59917,"source":{"system":"sec-edgar","filing":"0001209191-22-023285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122023285/doc4.xml","form_type":"4"}},{"id":2304615,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:23:50.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":7621,"price":5.97,"value":45497.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021."}],"balance_after":67538,"source":{"system":"sec-edgar","filing":"0001209191-22-023285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122023285/doc4.xml","form_type":"4"}},{"id":2391971,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-17T02:36:42.000Z","date":"2022-02-14","kind":"tax_withholding","acquired":false,"shares":5533,"price":14.27,"value":78955.91,"ownership":{"direct":true},"balance_after":59917,"source":{"system":"sec-edgar","filing":"0001209191-22-010483","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122010483/doc4.xml","form_type":"4"}},{"id":2391970,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-17T02:36:42.000Z","date":"2022-02-14","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person was issued 80,000 Restricted Stock Units (\"RSUs\") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On February 14, 2022, upon the occurrence of the second performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":65450,"source":{"system":"sec-edgar","filing":"0001209191-22-010483","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122010483/doc4.xml","form_type":"4"}},{"id":2419367,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-02T01:50:20.000Z","date":"2022-01-28","kind":"tax_withholding","acquired":false,"shares":5533,"price":11.69,"value":64680.77,"ownership":{"direct":true},"balance_after":49450,"source":{"system":"sec-edgar","filing":"0001209191-22-006142","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122006142/doc4.xml","form_type":"4"}},{"id":2419366,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-02T01:50:20.000Z","date":"2022-01-28","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person was issued 80,000 Restricted Stock Units (\"RSUs\") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On January 28, 2022, upon the occurrence of the first performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":54983,"source":{"system":"sec-edgar","filing":"0001209191-22-006142","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122006142/doc4.xml","form_type":"4"}},{"id":2437796,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-11T21:40:21.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Grant Date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates."}],"balance_after":125000,"derivative":{"exercise_price":15.52,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-22-002880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122002880/doc4.xml","form_type":"4"}},{"id":2549085,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:11:46.000Z","date":"2021-10-01","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was issued Restricted Stock Units (\"RSU\"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023.  The remaining shares shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement.  The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":86983,"source":{"system":"sec-edgar","filing":"0001209191-21-059571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919121059571/doc4.xml","form_type":"4"}},{"id":2677753,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-06-09T01:35:55.000Z","date":"2021-06-04","kind":"exercise","acquired":false,"shares":6983,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation (\"Old Adicet\"), for $0.740 per share in connection with the merger (the \"Merger\") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation (\"resTORbio\"). On the effective date of the Merger, resTORbio changed its name to \"Adicet Bio, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option vested on September 23, 2020, and 1/36th of the remaining unvested option vests on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Dr. Galimi remains in continuous service as of the applicable vesting date."}],"balance_after":121441,"derivative":{"exercise_price":5.97,"expiration_date":"2029-10-15","underlying":"Common Stock","underlying_shares":6983},"source":{"system":"sec-edgar","filing":"0001209191-21-039073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919121039073/doc4.xml","form_type":"4"}},{"id":2677752,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-09T01:35:55.000Z","date":"2021-06-04","kind":"exercise","acquired":true,"shares":6983,"price":5.97,"value":41688.51,"ownership":{"direct":true},"balance_after":6983,"source":{"system":"sec-edgar","filing":"0001209191-21-039073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919121039073/doc4.xml","form_type":"4"}},{"id":2855012,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T02:06:37.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":28400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates."}],"balance_after":28400,"derivative":{"exercise_price":16.82,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":28400},"source":{"system":"sec-edgar","filing":"0000899243-21-007018","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924321007018/doc4.xml","form_type":"4"}},{"id":2906145,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-15T21:30:11.000Z","date":"2021-01-13","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates."}],"balance_after":80000,"derivative":{"exercise_price":13.27,"expiration_date":"2031-01-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-21-002191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924321002191/doc4.xml","form_type":"4"}},{"id":3028649,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2020-09-18T01:48:02.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":77269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares of common stock subject to the option shall vest on each of the forty-eight (48) monthly anniversaries of the vesting commencement date, provided that Dr. Galimi remains in continuous service as of the applicable vesting date."}],"balance_after":77269,"derivative":{"exercise_price":16.11,"expiration_date":"2030-09-16","underlying":"Common Stock","underlying_shares":77269},"source":{"system":"sec-edgar","filing":"0000899243-20-025640","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924320025640/doc4.xml","form_type":"4"}},{"id":3028648,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":54833,"kind":"person","name":"Galimi Francesco","position":1,"cik":"0001823996","reported_name":"Galimi Francesco","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-18T01:48:02.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":128424,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation (\"Old Adicet\"), for $0.740 per share in connection with the merger (the \"Merger\") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation (\"resTORbio\").  On the effective date of the Merger, resTORbio changed its name to \"Adicet Bio, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option will vest on September 23, 2020, and 1/36th of the remaining unvested option will vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Dr. Galimi remains in continuous service as of the applicable vesting date."}],"balance_after":128424,"derivative":{"exercise_price":5.97,"expiration_date":"2029-10-15","underlying":"Common Stock","underlying_shares":128424},"source":{"system":"sec-edgar","filing":"0000899243-20-025640","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924320025640/doc4.xml","form_type":"4"}}]}